NPPA denies price hike on Sanofi, Novartis, and Allergan products.
The results declared by key companies for the three months ended March 31 show most firms have managed to arrest the moderation in volume growth witnessed in previous quarters.
This follows a series of tax notices to broadcasters to pay TDS on the 15% agency commission reflected in their invoices
Bharti was talking to Standard Chartered Bank and Citibank, among others, to manage the issue.
The Japanese giant wants to focus on segments outside its core business
Harish Manwani, HUL's chairman, responded to questions from Viveat Susan Pinto on how his company managed to buck the trend after struggling for much of the financial year ended March 31.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
The sensitivity segment has quadrupled in the past two years, due to the aggressive marketing effort of both GSK and Colgate.
This is going to be the lowest price for a Coke product in the non-returnable ready-to-drink category.
Data contradict Swiss drug major's claim that India does not respect IPR.
Three recalls of Goafest's award-winning campaigns in one week.
Unilever, which derives 52-53 per cent of its $70-billion revenues from emerging markets, said it expected economic pressures to continue in 2013.
Says tradability will ensure greater economic efficiency & higher revenues for the government.
Client-agency relationship comes under scrutiny at Goafest 2013.
In talks with BSNL, MTNL to float a firm in which it will hold 49 per cent.
DoT's data is based on inputs from the Telecom Regulatory Authority of India and service providers.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances